BMS 186511

prodrug for BMS-185878, a farnesyltransferase inhibitor withstructural motifs of farnesyl pyrophosphate and the CAAX tetrapeptide; structure given in first source

Also Known As:

BMS-186511

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - BMS 186511: 1
Inorganic Chemicals: 9
- Acids: 53217
  - Noncarboxylic Acids
    - Phosphorus Acids: 1
      - Phosphinic Acids: 18
        BMS 186511: 1
- Phosphorus Compounds: 84
  - Phosphorus Acids: 1
    - Phosphinic Acids: 18
      - BMS 186511: 1
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Phosphinic Acids: 18
    - BMS 186511: 1

Related Diseases

1.	Neurofibrosarcoma (MPNST) 08/15/1995 - "Thus, in the current study, we investigated whether BMS-186511, a bisubstrate analogue inhibitor of FT, would inhibit the malignant growth properties of a cell line established from malignant schwannoma of an NF1 patient. "